Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

79.66 +2.68 (+3.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗

November 22, 2025

Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential.

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗

November 14, 2025

Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗

October 27, 2025

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Via The Motley Fool

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

An Overview of Tarsus Pharmaceuticals's Earnings ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts ↗

January 27, 2025

Via Benzinga

3 Biotech Catalysts Present Major Opportunity ↗

August 25, 2025

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Via MarketBeat

Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗

August 20, 2025

Via Benzinga

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 27, 2025

Via Benzinga

6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗

May 05, 2025

Via Benzinga

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗

May 05, 2025

Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Earnings Outlook For Tarsus Pharmaceuticals ↗

November 12, 2024

Via Benzinga

Analyst Ratings For Tarsus Pharmaceuticals ↗

May 09, 2024

Via Benzinga

Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick? ↗

April 23, 2025

Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS).

Via Chartmill

Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) ↗

April 01, 2025

A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS).

Via Chartmill

How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run ↗

December 26, 2024

The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next.

Via Investor's Business Daily

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 15, 2024

Via Benzinga

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

October 28, 2024

Via Benzinga

TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 13, 2024

Via Benzinga

Simple Ways To Stay With Trends: The Week In Charts ↗

May 12, 2024

Has the market made its all-time highs? In this video I cover the stock and crypto markets.

Via Talk Markets

Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗

May 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

Headline News about Tarsus Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today